Alopecia Pipeline, Clinical Trials, and Key Companies Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical

June 01 13:08 2023
Alopecia Pipeline, Clinical Trials, and Key Companies Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical
DelveInsight Business Research LLP
(United States, Nevada, Las Vegas), DelveInsight’s “Alopecia – Pipeline Insight, 2023,” report provides comprehensive insights about 33+ companies and 33+ pipeline drugs in the Alopecia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Alopecia – Pipeline Insight, 2023,” report provides comprehensive insights about 33+ companies and 33+ pipeline drugs in the Alopecia pipeline landscape.

Key Takeaways from the Alopecia Pipeline Report

  • Over 33+ companies and 33+ pipeline drugs in Alopecia are in various stages of development, and their anticipated acceptance in the Alopecia market would significantly increase market revenue. 
  • Leading Alopecia companies developing novel drug candidates to improve the Alopecia treatment landscape include Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical, Pfizer, Biosplice Therapeutics, Inc., Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare SA, Eurofarma Laboratorios S.A., 3SBio, Arena Pharmaceuticals, AnaptysBio, Inc., Reistone Biopharma Company Limited, Biosplice Therapeutics, Inc., LEOPharma, Intrepid Therapeutics and others.
  • Promising Alopecia  pipeline therapies in various stages of development include KX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 ,  CTP-543, PF-06651600, and others 

Alopecia  Overview

Alopecia is the loss of hair in areas anywhere on the body where hair normally grows. Alopecia may be defined as scarring or non-scarring, localized or diffuse, congenital or acquired, reversible or permanent, or confined to the scalp or universal; however, alopecia is usually classified using the 1st 3 factors. The etiologies of alopecia are usually divided into disorders in which the hair follicle is abnormal or damaged and those in which the hair follicle is normal but the cycling of hair growth is abnormal. The most common presentations are androgenetic hair loss, alopecia areata, traction alopecia, tinea capitis, and telogen effluvium. Diagnosis is made through a positive medical history and physical exam findings. Treatment depends on the type and potential for regrowth.

Alopecia Pipeline Analysis: Drug Profile

KX-826: Kintor Pharma

KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of androgenetic alopecia (AGA) and acne vulgaris. For the AGA indication, on 8 September 2021, Kintor Pharma announced that the primary endpoint of phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile.

Baricitinib: Reata Pharmaceuticals

Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signaling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signaling molecules and proinflammatory mediators.

Discover more about the emerging Alopecia  drugs @ Alopecia Treatment Drugs

Alopecia  Pipeline Therapies and Key Companies

  • KX-826: Kintor Pharma
  • Baricitinib: Reata Pharmaceuticals

And many others 

Alopecia  Pipeline Therapeutics Assessment

Phases

DelveInsight’s Report covers around 33+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Molecule Type

 

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Alopecia Pipeline Report 

  • Coverage: Global 
  • Key Alopecia  Companies: Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical, Pfizer, Biosplice Therapeutics, Inc., Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare SA, Eurofarma Laboratorios S.A., 3SBio, Arena Pharmaceuticals, AnaptysBio, Inc., Reistone Biopharma Company Limited, Biosplice Therapeutics, Inc., LEOPharma, Intrepid Therapeutics and others.
  • Key Alopecia Pipeline Therapies:  KX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 ,  CTP-543, PF-06651600 and others.
  • Find out more about the Alopecia  treatment options in development @ Alopecia  Clinical Trials

Table of Contents

1. Alopecia   Introduction

2. Alopecia  Executive Summary

3. Alopecia   Overview

4. Alopecia   Pipeline Therapeutics

5. Alopecia  Late-Stage Products (Phase III)

6. Alopecia  Mid-Stage Products (Phase  II)

7. Alopecia  Early Stage Products (Phase  I/II)

8. Alopecia  Preclinical Stage Products

9. Alopecia  Discovery Stage Products

10. Alopecia  Therapeutic Assessment

11. Alopecia  Inactive Products

12. Alopecia  Collaborations Assessment- Licensing / Partnering / Funding

13. Alopecia  Unmet Needs

14. Alopecia   Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

  Categories: